TY - JOUR
T1 - Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome
AU - Amselem, Luis
AU - Montero, Javier
AU - Diaz-Llopis, Manuel
AU - Pulido, Jose S.
AU - Bakri, Sophie J.
AU - Palomares, Paula
AU - Garcia-Delpech, Salvador
N1 - Funding Information:
This study was supported in part by an unrestricted grant from Research to Prevent Blindness, Inc, New York, New York. The authors indicate no financial conflict of interest. Involved in design of study (L.A., J.M., M.D., J.P., S.B., S.G.); conduct of study (L.A., S.G.); collection of the data (L.A., J.M., P.M.); management of the data (L.A., J.M., P.P.); analysis of the data (L.A., J.M., M.D.); interpretation of the data (L.A., J.M., M.D.); preparation of the manuscript (L.A., M.D., J.P., S.B.); review of the manuscript (L.A., J.P., S.B.); and approval of the manuscript (L.A., J.P., S.B., M.D., J.M., S.G., P.P.).
PY - 2007/7
Y1 - 2007/7
N2 - Purpose: To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS). Design: Interventional case reports. Methods: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications. Results: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present. Conclusions: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.
AB - Purpose: To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS). Design: Interventional case reports. Methods: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications. Results: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present. Conclusions: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.
UR - http://www.scopus.com/inward/record.url?scp=34250782794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250782794&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2007.02.037
DO - 10.1016/j.ajo.2007.02.037
M3 - Article
C2 - 17601432
AN - SCOPUS:34250782794
SN - 0002-9394
VL - 144
SP - 122
EP - 124
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 1
ER -